@phdthesis{Duttu2005,
  author    = {Duttu, Vallabhapurapu Subrahmanya},
  title     = {Regulation of B lymphocyte terminal differentiation and death by the transcription factor Blimp-1},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-17158},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2005},
  abstract  = {B lymphocyte induced maturation protein-1 (Blimp-1) und X-box-binding protein-1" (XBP-1) sind als Transkriptionsfaktoren unverzichtbar f{\"u}r die terminale Differenzierung von B-Lymphozyten zu Immunglobulin (Ig)-sezernierenden Plasmazellen. Ebenso stellen die unfolded protein response (UPR) und das Spleißen von XBP-1, beides ausgel{\"o}st durch erh{\"o}hte Ig-Produktion, entscheidende Schritte auf dem Weg zur Plasmazellentstehung dar. Allerdings ist das Molek{\"u}l/ sind die Molek{\"u}le nach wie vor unbekannt, die diesen beiden Ereignissen in der Signalkaskade vorgeschaltet sind. Da die ektope Expression von Blimp-1 in B-Zellen hinreicht, diese zu Plasmazellen zu differenzieren, erscheint es plausibel, dass Blimp-1 das Molek{\"u}l sein k{\"o}nnte, das die Ausl{\"o}sung einer UPR und das Spleißen von XBP-1 steuert. Dieser M{\"o}glichkeit wurde durch ektope Expression von Blimp-1 in der Maus-B-Zell-Lymphomlinie WEHI 231 und in prim{\"a}ren B-Zellen aus der Milz von M{\"a}usen nachgegangen. Die ektope Expression von Blimp-1 f{\"u}hrte in beiden Zelltypen zur Erh{\"o}hung der Ig Produktion, zum Spleißen von XBP-1 und zur Sekretion von Immunglobulinen. Interessanterweise war der N-terminale Anteil von Blimp-1, bestehend aus den Aminos{\"a}uren 1-751, hinreichend, um diese Effekte auszul{\"o}sen, w{\"a}hrend der C-Terminus, der die Aminos{\"a}uren 465-856 umfaßte, keinen Effekt hatte. Dar{\"u}berhinaus, wurde die Expression von BIP, dessen Gen ein UPR-Zielgen ist, durch ektope Expression von Blimp-1 bzw. dessen N-Terminus in prim{\"a}ren B-Zellen erh{\"o}ht. Diese Ergebnisse zeigen deutlich, dass Blimp-1, speziell dessen N-terminale Dom{\"a}ne, hinreichend ist, um eine UPR und die Prozessierung von XBP-1 auszul{\"o}sen, was zur Ig-Sekretion von B-Zellen f{\"u}hrt.},
  subject      = {B-Lymphozyt},
  language  = {en}
}
@phdthesis{Sienerth2010,
  author    = {Sienerth, Arnold R.},
  title     = {Regulation of anti-inflammatory cytokine IL-10 by the Polycomb Group Protein Bmi1},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-49990},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2010},
  abstract  = {Macrophages are important effector cells of the innate and adaptive immune response and exert a wide variety of immunological functions which necessitates a high level of plasticity on the chromatin level. In response to pathogen-associated molecular patterns (PAMPs) or inflammatory signals macrophages undergo a process of cellular activation which is associated with morphologic, functional and biochemical changes. Toll-like receptors (TLR) are able to sense many different PAMPs. TLR4 is an important sensor for lipopolysaccharide (LPS) which elicits a major portion of the host's inflammatory response through the activation of many different signaling pathways such as the NF-\&\#954;B and the MAPK protein kinase pathways RASRAF- MEK-ERK, p38 and JNK. Polycomb group (PcG) proteins are well known chromatin modifiers which function in large complexes and are required to maintain chromatin structure in a transcriptionally repressed state. It has previously been shown that the PcG protein Bmi1 is phosphorylated by 3pK, a downstream effector kinase of the MAPK protein kinase pathways RAS-RAF-MEK-ERK, p38 and JNK. In this work I analyzed the role of Bmi1 as a downstream effector of MAPK signaling during macrophage activation. Unexpectedly a rapid up-regulation on the Bmi1 protein level was observed in bone marrow derived macrophages (BMDMs) after LPS treatment. The Bmi1 induction was associated with transient protein phosphorylation that occured downstream of MAPK signaling. LPS treatment of BMDMs in the absence of Bmi1 resulted in a pronounced increase of IL-10 secretion. This secretion of the anti-inflammatory cytokine IL-10 was associated with increased IL-10 mRNA levels. Furthermore, siRNA mediated knock down of Bmi1 in J774A.1 macrophages also resulted in elevated IL-10 mRNA levels in response to LPS. ChIP analysis revealed that Bmi1 binds to throughout the il-10 locus. Alternative activation of wild type BMDMs via concomitant TLR4 and Fc\&\#947;R activation which triggers high IL-10 expression is paralleled by an attenuated Bmi1 protein expression. These results identify Bmi1 as a repressor of IL-10 expression during activation of macrophages.},
  subject      = {Interleukin 10},
  language  = {en}
}
@phdthesis{Ashour2020,
  author    = {Ashour, DiyaaEldin},
  title     = {Kinetics and timing of IL-12 production by dendritic cells for Th1 polarization \(in\) \(vivo\)},
  doi       = {10.25972/OPUS-17948},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-179483},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2020},
  abstract  = {Auf Dendritische Zellen (DCs) basierende Vakzinen h{\"a}ngen von der Qualit{\"a}t der DC-Reifung ab, um Antigenpr{\"a}sentation, Kostimulation, Lymphknotenmigration und, im Faller einer T-Helfer-1 (Th1) Polarisierung, die Freisetzung von IL-12 zu induzieren. Die Herstellung des heterodimeren IL-12p70 durch injizierte DC wurde klassisch als Schl{\"u}sselfaktor beschrieben, der f{\"u}r die Erzeugung einer polarisierten Th1 Immunreaktion erforderlich ist. Dennoch induzieren DCs, die IL-12 nicht ausscheiden k{\"o}nnen (z. B. nach Reifung des Cytokin-Cocktails), Th1 polarisierte Immunantwortenin M{\"a}usen und Menschen. Da zuvor auch beschrieben wurde, dass DCs in der Lage sind, andere DCs auf Bystander-Weise zu aktivieren, haben wir hier die DC-Quelle der IL-12 Produktion f{\"u}r die Th1-Polarisation in einem murinen DC-Vakzinemodell untersucht. Die Migration der injizierten, aus murinem Knochenmark generierten DCs (BM-DCs) war f{\"u}r den Antigentransport in den Lymphknoten wesentlich. Sie trugen jedoch nur teilweise zur Antigenpr{\"a}sentation bei und induzierten nur einen nicht polarisierten Th0-Zustand der T-Zellen, die IL-2 produzierten, aber kein IFN-. Stattdessen deuten die Daten daraufhin, dass endogene dermale migrierende XCR1+ DCs als Bystander-DCs zur Antigenpr{\"a}sentation beitragen und IL-12 f{\"u}r die Th1 Polarisation bereitstellten. Die genetische Ablation von migrierenden DCs und speziell von XCR1+ migrierenden DCs hebt das Th1 Priming vollst{\"a}ndig auf, Die Kinetik der Wechselwirkungen in den drainierenden Lymphknoten erfolgt schrittweise, indem i) injizierte DCs mit verwandten T-Zellen, ii) injizierte DCs mit Bystander XCR1+ DCs und iii) Bystander XCR1+ DCs mit T-Zellen in Kontakt treten. Das Transkriptom der Bystander-DCs zeigte eine Herunterregulierung von Treg- und Th2/Th9-induzierenden Genen und eine Hochregulierung der f{\"u}r die Th1- Induktion erforderlichen Gene. Zusammen zeigen diese Daten, dass injizierte reife migrierende BM-DCs das T-Zell-Priming und die Bystander-DC-Aktivierung steuern, nicht jedoch die Th1-Polarisation, die durch endogene IL-12p70+ XCR1+ Bystander-DCs vermittelt wird. Unsere Ergebnisse sind von Bedeutung f{\"u}r klinische Studien mit Vakzine-DCs, bei denen endogene DCs durch eine Chemotherapie funktionell beeintr{\"a}chtigt werden k{\"o}nnen.},
  subject      = {Immunologie},
  language  = {en}
}
@article{RibechiniEckertBeilhacketal.2019,
  author    = {Ribechini, Eliana and Eckert, Ina and Beilhack, Andreas and Du Plessis, Nelita and Walzl, Gerhard and Schleicher, Ulrike and Ritter, Uwe and Lutz, Manfred B.},
  title     = {Heat-killed Mycobacterium tuberculosis prime-boost vaccination induces myeloid-derived suppressor cells with spleen dendritic cell-killing capability},
  series = {JCI Insight},
  volume    = {13},
  journal   = {JCI Insight},
  number    = {4},
  doi       = {10.1172/jci.insight.128664},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-201973},
  pages     = {e128664},
  year      = {2019},
  abstract  = {Tuberculosis patients and mice infected with live Mycobacterium tuberculosis accumulate high numbers of myeloid-derived suppressor cells (MDSCs). Here, we hypothesized that dead M. tuberculosis vaccines also may induce MDSCs that could impair the efficacy of vaccination. We found that repeated injections of M. tuberculosis vaccines (heat-killed M. tuberculosis in incomplete Freund's adjuvant, such as Montanide) but not single or control vaccines without M. tuberculosis strongly expanded CD11b\(^+\) myeloid cells in the spleen, leading to T cell suppression of proliferation and killing ex vivo. Dead M. tuberculosis vaccination induced the generation of CD11b\(^+\)Ly6C\(^{hi}\)CD115\(^+\) iNOS/Nos2\(^+\) monocytic MDSCs (M-MDSCs) upon application of inflammatory or microbial activation signals. In vivo these M-MDSCs were positioned strategically in the splenic bridging channels and then positioned in the white pulp areas. Notably, within 6-24 hours, in a Nos2-dependent fashion, they produced NO to rapidly kill conventional and plasmacytoid DCs while, surprisingly, sparing T cells in vivo. Thus, we demonstrate that M. tuberculosis vaccine induced M-MDSCs do not directly suppress effector T cells in vivo but, instead, indirectly by killing DCs. Collectively, we demonstrate that M. tuberculosis booster vaccines induce M-MDSCs in the spleen that can be activated to kill DCs. Our data suggest that formation of MDSCs by M. tuberculosis vaccines should be investigated also in clinical trials.},
  language  = {en}
}
@phdthesis{Mahmood2015,
  author    = {Mahmood, Zafar},
  title     = {Effect of cytokine inhibition on peripheral memory B cells in patients with Rheumatoid arthtritis},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-117334},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2015},
  abstract  = {Objective: Rheumatoid arthritis (RA) is a chronic, systemic, inflammatory autoimmune disease. Enhanced B cell activity has been proposed in the pathogenesis of RA along with different pro-inflammatory cytokines such as interleukin 6 (IL-6) and tumor necrosis factor alpha (TNF-α), critically involved in chronic inflammation. Biological agents targeting these cytokines IL-6 and TNF-α have considerably advanced treatment of autoimmunity. Enhanced B cell activity, particularly memory B cells gained particularly interest in evaluating response during therapies from biologics. Human peripheral memory B cells can be distinguished by the phenotypic expression of CD27 and IgD defining three major B cell subpopulations: CD27+IgD+ pre-switch, CD27+IgD- post-switch and CD27-IgD- double negative (DN) memory B cells. Therefore, we analyzed different memory populations during cytokine inhibition by using tocilizumab (anti-IL-6R, TCZ) and adalimumab (anti-TNF-α, ADA), with focus on DN B cells Suspended. DN B cells lacking the conventional memory marker CD27, but due to their mutational Ig repertoire (IgR) considered in the memory compartment. However, only scare data are available for this DN subpopulation in RA. Methods: Phenotype analysis of activation markers (CD95 and ki-67) of B cell and their subsets were compared in RA patients (median age ~56 years) and in HD. DN memory B cells were phenotypically analyzed from RA patients during IL-6R or TNF-α inhibition at baseline week 12, week 24 and 1 year. Single B cell PCR approach was used to study Ig- receptors VH genes and isotype specific genes. Nonparametric Wilcoxon matched pair test and Mann-Whitney U test was used for statistical analysis by using GraphPadPrism 5. Univariate logistic regression was used to calculate odd ratios and correlation using Pearson r using SPSS statistics 22. Results: Surface and intracellular staining of B cells showed a significantly higher percentage of CD95 and ki-67 expressions in RA, which was highest in post-switch memory B cells followed by pre-switch and DN memory B cells. During cytokines (IL-6R \& TNF-α) inhibition, both CD95 and ki-67 expression were significantly reduced at week 12 and 24 along with reduction in their clinical parameters like DAS28, CRP, ESR. Furthermore, the phenotypic analysis in 107 RA patients and 49 healthy donors (HD) showed a significantly expanded population of DN B cells in RA which contain a heterogeneous mixture of IgA, IgG and IgM expressing cells with a clear dominance of IgG+ cells. Pre-therapy analysis of rearranged IgR sequences from patients (n=9) revealed that DN B cells carry rearranged heavy chain gene sequences with a diversified mutational pattern consistent with memory B cells. In contrast to tumor necrosis factor alpha (TNF-alpha) inhibition, a significant reduction in mutational frequency of BCR gene rearrangements at week 12, 24 and 1 year (p < 0.0001) was observed by in vivo IL-6R inhibition. These changes were observed for all BCR isotypes IgG, IgA and IgM at week 12, 24 and 1 year (p < 0.0001). IgA-RF, IgA serum level and IgA+ DN B cells decreased significantly (p < 0.05) at week 12 and week 24 during TCZ. Patients with a good European league against rheumatism (EULAR) response to TCZ had less DN B cells at baseline as compared to moderate responders (p = 0.006). Univariate logistic regression analysis revealed that the frequency of DN B cells at baseline is inversely correlated to a subsequent good EULAR response (p = 0.024) with an odds ratio of 1.48 (95\% confidence interval as 1.05-2.06). Conclusion: Both anti-TNF-α and anti-IL-6R could reduce higher B cell activity and improve disease activity tremendously in RA patients. The heterogeneous DN B cell compartment is expanded in RA and dominated by IgG isotype. TCZ can modulate the mutational status of DN Ig isotype receptors over 1 year. Interestingly, the frequency of DN B cells in RA may serve as a baseline predictor of subsequent EULAR response to TCZ.},
  subject      = {Arthrosis deformans},
  language  = {en}
}